---
schema_version: "secwatch.filing_event.v1"
accession: "0001739104-23-000021"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:32:46.353375+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Elanco reports Q3 2023 net loss of $1,096M on $1,042M goodwill impairment; raises adjusted EPS guidance

## Summary
- Revenue $1,068M (+4% reported, +5% CC); Pet Health +6% CC, Farm Animal +4% CC.
- Reported net loss $1,096M includes $1,042M goodwill impairment; adjusted EPS $0.18 (up 6% YoY).
- Full-year 2023 guidance tightened: revenue $4,360-4,400M, adj. EPS $0.88-0.94 (prior $0.80-0.89).
- Net leverage ratio 5.7x; Q4 guidance: revenue $978-1,018M, adj. EPS $0.07-0.13.
- CEO: innovation pipeline Credelio Quattro, Bovaer, Zenrelia on track for H1 2024 US approvals.

## SEC filing metadata
- accession: 0001739104-23-000021
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000173910423000021/0001739104-23-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000173910423000021/elan-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739104-23-000021
- JSON: https://secwatch.observer/filing/0001739104-23-000021.json
- Plain text: https://secwatch.observer/filing/0001739104-23-000021.txt

## Key facts
- Earnings Releases
  Elanco Animal Health Inc reported the fiscal quarter ended September 30, 2023 results: revenue Revenue of $1,068 million, net income Reported Net Loss of $1,096 million, EPS Reported EPS of $(2.22).
  - Period: the fiscal quarter ended September 30, 2023
  - Revenue: Revenue of $1,068 million
  - Net income: Reported Net Loss of $1,096 million
  - EPS: Reported EPS of $(2.22)
  - Result: reported results
  source text: Elanco Animal Health Reports Third Quarter 2023 Results • Third Quarter 2023 Financial Results ◦ Revenue of $1,068 million, representing 4% reported growth or 5% excluding the impact of foreign exchange rates ◦ Reported Net Loss of $1,096 million, inclusive of a non-cash goodwill impairment charge of $1,042 million primarily related to increased long-term treasury rates ◦ Adjusted EBITDA of $214 million, or 20.0% of Revenue ◦ Reported EPS of $(2.22) inclusive of a $(2.10) per share impact of goodwill impairment charge, Adjusted EPS of $0.18
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739104/000173910423000021/0001739104-23-000021-index.htm
- Earnings Releases
  Elanco Animal Health Inc reported full year 2023 results: revenue Revenue of $4,360 to $4,400 million, net income Reported Net Loss of $1,174 to $1,204 million, EPS Reported diluted EPS of $(2.43) to $(2.37).
  - Period: full year 2023
  - Revenue: Revenue of $4,360 to $4,400 million
  - Net income: Reported Net Loss of $1,174 to $1,204 million
  - EPS: Reported diluted EPS of $(2.43) to $(2.37)
  - Result: guidance update
  source text: Updating full year 2023 guidance to reflect third quarter outperformance offset by expected unfavorable impact of foreign exchange rates: ◦ Revenue of $4,360 to $4,400 million, constant currency growth improves to flat to 1% ◦ Reported Net Loss of $1,174 to $1,204 million, Reported diluted EPS of $(2.43) to $(2.37) ◦ Adjusted EPS of $0.88 to $0.94, Adjusted EBITDA of $965 to $1,000 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739104/000173910423000021/0001739104-23-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.